middle.news
PYC Therapeutics Advances ADOA Trial with Key Dose Escalation Approval
9:32am on Friday 31st of January, 2025 AEDT
•
Biotechnology
Read Story
PYC Therapeutics Advances ADOA Trial with Key Dose Escalation Approval
9:32am on Friday 31st of January, 2025 AEDT
Key Points
Safety Review Committee approves dose escalation from 3µg to 10µg in ADOA trial
PYC-001 targets underlying genetic cause of Autosomal Dominant Optic Atrophy
Trial progression aims to generate safety and efficacy data throughout 2025
ADOA affects approximately 1 in 35,000 people with no existing treatments
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PYC Therapeutics (ASX:PYC)
OPEN ARTICLE